(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma

Patients with non-Hodgkin lymphoma (NHL) who are treated with rituximab may develop resistant disease, often associated with changes in expression of CD20. The next-generation β-particle–emitting radioimmunoconjugate (177)Lu-lilotomab-satetraxetan (Betalutin) was shown to up-regulate CD20 expression...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Nucl Med
Auteurs principaux: Malenge, Marion M., Patzke, Sebastian, Ree, Anne H., Stokke, Trond, Ceuppens, Peter, Middleton, Brian, Dahle, Jostein, Repetto-Llamazares, Ada H.V.
Format: Artigo
Langue:Inglês
Publié: Society of Nuclear Medicine 2020
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539655/
https://ncbi.nlm.nih.gov/pubmed/32245896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.119.237230
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires